NASDAQ:ICAD - iCAD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 28.13 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$17.95
▲ +0.05 (0.28%)
1 month | 3 months | 12 months
Get New iCAD Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICAD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$23.00
▲ +28.13% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for iCAD in the last 3 months. The average price target is $23.00, with a high forecast of $27.00 and a low forecast of $19.00. The average price target represents a 28.13% upside from the last price of $17.95.
Buy
The current consensus among 7 polled investment analysts is to buy stock in iCAD.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/22/2021GuggenheimInitiated CoverageBuy$24.00Low
i
3/29/2021BTIG ResearchInitiated CoverageBuy$25.00High
i
3/23/2021BTIG ResearchInitiated CoverageBuy$25.00High
i
3/3/2021OppenheimerInitiated CoverageOutperform$27.00High
i
2/26/2021B. RileyBoost Price TargetBuy$18.00 ➝ $23.00High
i
Rating by A. D'silva at B. Riley
2/25/2021OppenheimerInitiated CoverageOutperform$27.00High
i
2/25/2021Craig HallumBoost Price TargetBuy$15.00 ➝ $22.00High
i
2/25/2021Lake Street CapitalBoost Price TargetBuy$17.00 ➝ $21.00High
i
1/28/2021Cantor FitzgeraldInitiated CoverageOverweight$19.00High
i
Rating by K. Mikson at Cantor Fitzgerald
12/15/2020B. RileyBoost Price TargetBuy$15.00 ➝ $18.00High
i
Rating by A. D'silva at B. Riley
12/11/2020Lake Street CapitalBoost Price TargetBuy$14.00 ➝ $17.00High
i
12/3/2020B. RileyInitiated CoverageBuy$15.00High
i
Rating by A. D'silva at B. Riley
2/13/2020Craig HallumBoost Price TargetBuy$9.00 ➝ $15.00High
i
2/5/2020JMP SecuritiesInitiated CoverageOutperform$15.00Medium
i
1/9/2020Lake Street CapitalInitiated CoverageBuy$14.00High
i
12/20/2019Dougherty & CoInitiated CoverageBuy$10.00High
i
Rating by G. Mannheimer at Dougherty & Co
7/25/2017LaidlawReiterated RatingBuy$11.00Medium
i
(Data available from 4/22/2016 forward)
iCAD logo
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Today's Range

Now: $17.95
$17.62
$18.22

50 Day Range

MA: $18.70
$16.55
$21.22

52 Week Range

Now: $17.95
$8.32
$21.44

Volume

1,633 shs

Average Volume

207,699 shs

Market Capitalization

$447.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of iCAD?

The following Wall Street research analysts have issued stock ratings on iCAD in the last year: B. Riley, BTIG Research, Cantor Fitzgerald, Craig Hallum, Guggenheim, Lake Street Capital, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for ICAD.

What is the current price target for iCAD?

7 Wall Street analysts have set twelve-month price targets for iCAD in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 29.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting ICAD will reach $27.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $19.00 for iCAD in the next year.
View the latest price targets for ICAD.

What is the current consensus analyst rating for iCAD?

iCAD currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ICAD will outperform the market and that investors should add to their positions of iCAD.
View the latest ratings for ICAD.

What other companies compete with iCAD?

How do I contact iCAD's investor relations team?

iCAD's physical mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company's listed phone number is 603-882-5200 and its investor relations email address is [email protected] The official website for iCAD is www.icadmed.com.